Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTarget
2019-004771-40Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib, alectinib, atezolizumab, cobimetinib, vemurafenib and 8 more in cancer, sponsored by Rigshospitalet. Primary endpoint: Objective response. Started Jan 2020; status: active.
02
Drugs
niraparibalectinibatezolizumabcobimetinibvemurafenib
03
Conditions
cancer
Beyond the preview
Go deeper on 2019-004771-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004771-40.